Skip to main content

Table 1 The prevalence and genotype distribution of HPV in cervical lesions

From: Human papillomavirus infections among women with cervical lesions and cervical cancer in Yueyang, China: a cross-sectional study of 3674 women from 2019 to 2022

HPV

CINI (n = 1910)

CINII (n = 718)

CINIII (n = 576)

ICC (n = 470)

Total (n = 3674)

HPV (–)

637 (33.35)

138 (19.22)

93 (16.15)

62 (13.19)

930 (25.31)

Any HPV

1273 (66.65)

580 (80.78)

483 (83.88)

408 (86.81)

2744 (74.69)

High-risk HPV

1243 (65.08)

573 (79.81)

481 (83.51)

402 (85.53)

2699 (73.46)

16

240 (12.57)

150 (20.89)

213 (36.98)

239 (50.85)

842 (22.92)

52

379 (19.84)

192 (26.74)

99 (17.19)

69 (14.68)

740 (20.14)

58

198 (10.37)

136 (18.94)

130 (22.57)

72 (15.32)

536 (14.59)

53

151 (7.91)

58 (8.08)

20 (3.47)

20 (4.26)

249 (6.78)

51

139 (7.28)

65 (9.05)

18 (3.13)

14 (2.98)

236 (6.42)

68

94 (4.92)

38 (5.29)

15 (2.60)

9 (1.91)

156 (4.25)

33

76 (3.98)

45 (6.27)

72 (12.50)

24 (5.11)

217 (5.91)

39

100 (5.24)

38 (5.29)

16 (2.78)

19 (4.04)

173 (4.71)

56

79 (4.14)

26 (3.62)

18 (3.13)

14 (2.98)

138 (3.76)

18

108 (5.65)

41 (5.71)

17 (2.95)

27 (5.74)

194 (5.28)

66

61 (3.19)

17 (2.37)

4 (0.69)

4 (0.85)

86 (2.34)

59

63 (3.30)

18 (2.51)

3 (0.52)

11 (2.34)

95 (2.59)

31

49 (2.57)

34 (4.74)

31 (5.38)

18 (3.83)

133 (3.62)

35

24 (1.26)

14 (1.95)

6 (1.04)

7 (1.49)

51 (1.39)

45

29 (1.52)

6 (0.84)

8 (1.39)

3 (0.64)

46 (1.25)

Low-risk HPV

151 (7.91)

47 (6.55)

35 (6.08)

32 (6.81)

265 (7.21)

81

64 (3.35)

19 (2.65)

16 (2.78)

15 (3.19)

115 (3.13)

42

32 (1.68)

10 (1.39)

6 (1.04)

6 (1.28)

54 (1.47)

43

27 (1.41)

8 (1.11)

8 (1.39)

6 (1.28)

49 (1.33)

6

19 (0.99)

13 (1.81)

3 (0.52)

5 (1.06)

39 (1.06)

44

6 (0.31)

1 (0.14)

4 (0.69)

1 (0.21)

12 (0.33)

11

15 (0.79)

2 (0.28)

1 (0.17)

2 (0.43)

20 (0.54)

  1. The prevalence of HR-HPV in ICC is significantly different from that of in precancerous cervical lesions (CIN I, χ2 = 73.92, P < 0.001; CIN II, χ2 = 6.33, P = 0.012); except CINIII (CIN III, χ2 = 0.81, P = 0.369)
  2. The prevalence of HPV16 in ICC is significantly higher than that of in precancerous cervical lesions, P < 0.001 (CIN I, χ2 = 343.92; CIN II, χ2 = 115.78; CIN III, χ2 = 20.30)
  3. The prevalence of HPV type 16 in ICC is significantly higher than that of other high-risk HPV types, P < 0.001 (HPV52, χ2 = 139.56; HPV58, χ2 = 134.01; HPV18, χ2 = 235.65; HPV33, χ2 = 244.04)
  4. The prevalence of HPV52 was significantly higher than that of HPV16 in patients with CINI and CINII, P < 0.01 (CIN I, χ2 = 37.25, P < 0.001; CIN II, χ2 = 6.77, P = 0.009)